Introduction
============

Acute kidney injury (AKI), previously known as acute renal failure, indicates abrupt deterioration of renal function. While acute renal failure often implies anuria and urgent need of emergency renal replacement therapy (RRT), AKI is a broader term coined to detect this condition at an early stage, thereby improving its outcome through early intervention. AKI occurs in about 60% of patients in the intensive care unit (ICU). In fact, even early-stage AKI is proven to be associated with higher morbidity and mortality ([Fig. 1](#f1-kjp-2018-06996){ref-type="fig"}) \[[@b1-kjp-2018-06996]\], especially in critically ill patients. In addition, there is mounting evidence against the previous notion that no long-term sequelae can occur after complete resolution of acute renal failure; AKI is a risk factor for chronic kidney disease (CKD) \[[@b1-kjp-2018-06996]\]. Therefore, timely detection of and intervention for AKI are necessary to improve the short-term outcome of this condition and to prevent CKD.

Definition of AKI
=================

Authors of various studies previously used their own definitions of AKI, which have hindered appropriate collective studies on AKI. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) announced a new definition of AKI, summarizing the previously widely accepted criteria ([Table 1](#t1-kjp-2018-06996){ref-type="table"}) \[[@b2-kjp-2018-06996]\]. For neonates, modification of criteria of absolute creatinine level for stage III AKI was proposed as 2.5 mg/dL \[[@b3-kjp-2018-06996]\].

However, the definition of AKI based on serum creatinine level has several limitations. Serum creatinine is a functional marker of the kidney; its level increases hours or days after renal injury. Creatinine is dependent on muscle mass; fluid overload might dilute the serum creatinine concentration, and its clearance may be altered with the drug cimetidine or other organic molecules, as well as in systemic diseases. Notably, cystatin C, an inhibitor of cysteine proteinases from all nucleated cells \[[@b4-kjp-2018-06996]\], irrespective of muscle mass and age, is considered as an alternative for creatinine in estimating renal clearance. Glomerular filtration rate estimation equation using cystatin C was more accurate than that using creatinine \[[@b5-kjp-2018-06996]\]. However, cystatin C is affected by diabetes, high-dose corticosteroids, hyperthyroidism, inflammation, hyperbilirubinemia, rheumatoid factor, and hypertriglyceridemia \[[@b6-kjp-2018-06996]\].

Biomarkers of kidney injury, namely tubular injury markers of N-acetyl-β-D-glucosaminidase (proximal tubular damage marker), neutrophil gelatinase-associated lipocalin (approved in Korea and other countries), kidney injury molecule-1, liver fatty acid-binding protein (approved in Japan), and kidney stress and cell cycle arrest marker TIMP-2 & IGFBP-7 (NephroCheck \[Astute Medical, San Diego, CA, USA\], approved in USA) \[[@b7-kjp-2018-06996],[@b8-kjp-2018-06996]\], have been investigated and validated. However, these are not yet widely used in clinics \[[@b9-kjp-2018-06996]\].

Causes of AKI
=============

Once AKI is detected, a physician should determine its causes and manage them accordingly. Dehydration or decreased renal perfusion is the most common cause of AKI, followed by drug or nephrotoxininduced AKI \[[@b10-kjp-2018-06996],[@b11-kjp-2018-06996]\]. Glomerulopathies including hemolytic uremic syndrome and all kinds of glomerulonephritis often accompany AKI ([Table 2](#t2-kjp-2018-06996){ref-type="table"}) \[[@b6-kjp-2018-06996],[@b12-kjp-2018-06996],[@b13-kjp-2018-06996]\].

A type of infection-induced acute tubulointerstitial disease is noteworthy. When a child presents with prolonged fever of unknown origin followed by gastrointestinal symptoms of abdominal pain and diarrhea, leading to a diagnosis of AKI, *Yersinia pseudotuberculosis* infection should be considered \[[@b14-kjp-2018-06996]\]. *Y. pseudotuberculosis* infection is spread by consumption of unsanitized water, and it may be complicated by AKI, which is self-limiting. It often resembles Kawasakilike disease, with strawberry tongue, desquamation of the fingertips, and dilatation of coronary arteries ([Fig. 2](#f2-kjp-2018-06996){ref-type="fig"}) \[[@b14-kjp-2018-06996]\].

How to manage AKI
=================

There is no proven medication for AKI. Therefore, prevention and early detection is the mainstay of management of AKI.

1. Identification of at-risk patients, monitoring, and early detection
----------------------------------------------------------------------

In general, dehydration; advanced age or prematurity; chronic diseases, especially CKD, diabetes, hypertension, cancer, anemia, and proteinuria in adults render the host susceptible to AKI \[[@b15-kjp-2018-06996]\]; volume depletion, sepsis, critical illness, cardiopulmonary bypass, ICU care, extracorporeal membrane oxygenation, surgery, ventilation, vasopressor usage, and exposure to nephrotoxins lead to an increased risk of AKI ([Table 3](#t3-kjp-2018-06996){ref-type="table"}) \[[@b2-kjp-2018-06996],[@b16-kjp-2018-06996]\].

Every condition associated with AKI has its own risk factors; therefore, physicians should be aware of these risk factors for their disease of interest and should carefully monitor renal function in patients at risk of AKI \[[@b10-kjp-2018-06996]\]. For example, pediatric cardiac surgery; cyanotic heart disease; long extracorporeal circulation; higher risk according to the RACHS-1 (risk-adjusted classification for congenital heart surgery); postoperative low cardiac output syndrome; pump failure; sepsis; hematologic complications; preoperative dependency on the ventilator; treatment with milrinone, gentamicin, or furosemide; duration of anesthesia; use of multiple cross-clamps; and transfusion have been reported as risk factors for AKI \[[@b17-kjp-2018-06996],[@b18-kjp-2018-06996]\]. A kidney scoring system called renal angina index was proposed to predict AKI in critically ill children \[[@b16-kjp-2018-06996]\]. It predicted AKI on the basis of subtle kidney injury (change of estimated creatinine clearance, or fluid overload) and patient risk factors (ICU admission, stem cell transplantation, ventilation and inotropy) \[[@b16-kjp-2018-06996]\].

2. Optimization of volume status and circulation: avoid hypovolemia and fluid overload
--------------------------------------------------------------------------------------

Adequate renal perfusion is essential to prevent AKI and to recover from it. Optimal blood pressure and intravascular volume of the patient should be maintained (mean arterial pressure\>65 mmHg or higher for a previously hypertensive host, central venous pressure 8--12 mmHg for an adult). Fluid resuscitation is initially necessary for patients with hypotension, if the hypotension is partially due to hypovolemia; however, fluid overload (weight gain more than 10%) in critically ill patients is associated with a poor outcome; therefore, fluid administration should be cautiously performed. Meanwhile, as long as the intravascular volume is adequate, inotropics should be considered to ensure adequate (renal) circulation \[[@b19-kjp-2018-06996]-[@b24-kjp-2018-06996]\].

With regard to the choice of resuscitation fluid, studies have shown that patients treated with colloid solutions such as hydroxyethyl starches show poorer outcomes compared to outcomes in patients treated with normal saline. Albumin seems not inferior to saline, except in patients with traumatic brain injury \[[@b6-kjp-2018-06996],[@b25-kjp-2018-06996]\]. Some studies reported that normal saline leads to poorer outcomes than those observed using a balanced salt solution such as Ringers lactate solution. As normal saline is hyperchloremic, it could induce hyperchloremic metabolic acidosis, leading to decreased renal cortical tissue perfusion \[[@b26-kjp-2018-06996]\]. However, recent prospective studies failed to prove the efficacy of balanced solution over that of normal saline \[[@b27-kjp-2018-06996],[@b28-kjp-2018-06996]\].

3. Avoid nephrotoxic agents
---------------------------

Antibiotics such as aminoglycoside, vancomycin (especially when used along with piperacillin/tazobactam) \[[@b6-kjp-2018-06996]\], amphotericin, nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensinogenconverting enzyme inhibitor, angiotensin receptor blocker, calcineurin inhibitors, and chemotherapeutic agents such as cisplatin and methotrexate are well-known nephrotoxins. These nephrotoxins should be avoided in patients at risk of AKI and in those with established AKI. If the use of these agents is unavoidable, their dosage or dosing interval should be adjusted to reduce renal toxicity. For example, a once daily dose of aminoglycoside is less nephrotoxic than other regimens. In addition, the trough level should be measured and adjusted accordingly \[[@b29-kjp-2018-06996]\].

Contrast media used for angiography and computed tomography is nephrotoxic as well. Patients with CKD, diabetes, insufficient circulating blood volume, and those who take NSAIDs are at risk of contrast-induced AKI. Contrast dosage, type, and multiple procedures increase the risk of this condition. Minimization of contrastmedia volume, use of low-osmolar and iso-osmolar contrast media, and administration of noniodinated contrast media are recommended to prevent contrast-induced AKI \[[@b30-kjp-2018-06996]\]. Preventive measures include intravenous administration of an isotonic normal saline or Hartmann solution at 1 mL/kg/hr 12 hours before and after the procedure, or 3 mL/kg/hr 1 hour before and 6--9 mL/kg over 4--6 hours after the procedure \[[@b6-kjp-2018-06996],[@b30-kjp-2018-06996]\]. KDIGO guidelines suggest using N-acetylcysteine in patients at increased risk of contrast-induced AKI \[[@b30-kjp-2018-06996]\], while a recent randomized controlled trial failed to show any benefit of N-acetylcysteine \[[@b31-kjp-2018-06996]\]. In addition, nephrotoxins should be discontinued more than 24 hours before the procedure.

4. Nutritional support \[[@b6-kjp-2018-06996],[@b32-kjp-2018-06996]\]
---------------------------------------------------------------------

As AKI is a catabolic status, nutritional support is necessary; oral nutrition is preferred.

\- Plasma glucose 110--149 mg/dL (caution should be exercised, as patients with AKI are at risk of hypoglycemia)

\- Total energy intake of 20--30 kcal/kg/day in patients at any stage of AKI (no restriction!)

\- Protein 0.8--1.0 (1.5) g/kg/day in AKI (no RRT), 1.0--1.5 (3--4) g/kg/day on RRT, up to 1.7 g/kg/day on continuous RRT (CRRT)

5. Pharmacological intervention
-------------------------------

Diuretics are effective only for preventing/ameliorating fluid overload and not for maintaining urine output volume to avoid AKI. Diuretics are not recommended to prevent AKI or to treat established AKI \[[@b33-kjp-2018-06996]\]. Mannitol, dopamine (other than as an inotropic) \[[@b34-kjp-2018-06996]\], glucocorticoid \[[@b35-kjp-2018-06996]\], fenoldopam \[[@b36-kjp-2018-06996]\], and N-acetylcysteine \[[@b37-kjp-2018-06996],[@b38-kjp-2018-06996]\] (other than contrast-induced AKI) are also not recommended.

RRT for severe AKI
==================

1. When to start
----------------

RRT is indicated when metabolic derangement of AKI, such as hyperkalemia or acidosis, and/or fluid overload cannot be managed with medications, or for detoxification. Some researchers recommend early initiation of RRT, but available data show mixed results in this regard \[[@b39-kjp-2018-06996],[@b40-kjp-2018-06996]\]. Fluid overload of more than 10% of the body weight and inability to maintain input--output balance owing to large amount of fluid to treat the patients and/or oliguria are the common indications for RRT \[[@b41-kjp-2018-06996]\].

2. Which modality to use
------------------------

Intermittent hemodialysis (IHD), CRRT, and peritoneal dialysis (PD) are available as RRT for AKI. The choice of modality depends on availability at the center and the condition of the patient. IHD is possible only when the patient is hemodynamically stable, and when HD machine appropriate for the size of the patient, and dedicated personnel (pediatric nephrologist and dialysis nurses capable of performing pediatric IHD) are available. CRRT is a low-dose long-duration RRT; therefore, patients who are hemodynamically less stable can be managed with CRRT, usually in the ICU setting. However, it still requires appropriate machines suitable for CRRT in children. Although PD can be applied irrespective of the patient size, its dosage in critically ill patients is highly unpredictable, because dialysis is dependent on the peritoneal circulation. In addition, the risk of catheter-related infections is higher with PD, with a high risk of peritoneal fluid leakage through the PD catheter insertion site.

Recently, CRRT has become widely available for critically ill patients. Therefore, the following sections will focus on CRRT. In fact, several studies have shown that CRRT is superior to IHD for recovery from AKI, as interdialytic hypotension is more common in IHD than in CRRT.

3. Vascular access for CRRT
---------------------------

In children, adequacy of CRRT (and IHD) often depends on the adequacy of vascular access, which determines maximum blood flow rate (BFR) and filter lifespan \[[@b41-kjp-2018-06996]\]. The shortest and largest possible catheter for the patient are recommended for successful CRRT, which ensures lower resistance and better blood flow ([Table 4](#t4-kjp-2018-06996){ref-type="table"}). For AKI, dual or triple lumen catheter dedicated to RRT or 2 single lumen catheters are used. On the contrary, the smallest catheter to facilitate appropriate BFR is recommended to protect the vessel of the patient. The locations of vascular access are the internal jugular vein and femoral vein; subclavian vein should be avoided to prevent stenosis of ipsilateral arm veins. Complications of vascular access such as infection (high chance in femoral vein); thrombosis; stenosis; and problems of catheter itself such as malfunction, kinking of the catheter, and recirculation between input lumen and output lumen should be considered when choosing vascular access.

4. Prescription of CRRT
-----------------------

### 1) Choice of filter/membrane for CRRT

Once vascular access for dialysis is secured, the CRRT kit to be used should be determined based on patient weight. A filter/membrane with a surface area closest to the body surface area (BSA) of the patient should be chosen ([Table 5](#t5-kjp-2018-06996){ref-type="table"}). The extracorporeal blood volume necessary to use the respective circuit should be known; allowable extracorporeal volume is less than 8 mL/kg (\<10%--20% of the plasma volume). The difference between required circuit volume and allowable extracorporeal volume can be filled by priming the circuit with blood (blood priming) or 5% albumin.

### 2) Choice of CRRT mode

(Ultra)filtration (hemofiltration, HF) uses convection to remove fluid and its solute across the membrane by a transmembrane (hydrostatic) pressure gradient that is exerted by the pump of the CRRT machine; the removed fluid is replaced by adding "replacement fluid" through the prefilter or postfilter port of the CRRT circuit. Hemodialysis (HD) uses diffusion of solute between blood (plasma) and dialysate (flowing in a direction opposite to that of the plasma to maximize the solute concentration difference) through filter (membrane) by the concentration difference. Convection can remove larger molecules than diffusion does; therefore, if the target molecule is large, HF is the preferred mode of CRRT. With continuous venovenous hemodiafiltration (CVVHDF), HD and HF are applied simultaneously; their ratio can be decided according to the condition of the patient. If the target molecule is small, such as that of ammonia, the ratio of HD can be increased for faster removal of the molecule.

### 3) Choice of CRRT fluid

Patients who require CRRT often have severe AKI with hyperphosphatemia and hyperkalemia. Therefore, the components of CRRT fluid are designed to treat these metabolic derangements ([Table 6](#t6-kjp-2018-06996){ref-type="table"}). In case of normal phosphorous/potassium levels, the CRRT fluid of the patient needs to be supplemented with additional phosphorous/potassium. Commercialized CRRT fluids containing additional phosphorous/potassium are available.

### 4) Intensity of RRT

Creatinine clearance by CRRT is assumed to be equal to the effluent rate, as the creatinine concentration of the effluent from dialysis is equal to the serum creatinine (as long as the dialysis membrane is functional, because BFR is much higher than the counter-current dialysate flow rate \[DFR\]), and that of the effluent of ultrafiltration is equal to that of plasma (excluding large molecules that cannot pass the filtration). Although the optimal intensity of RRT is debatable, a filtration rate of 20--35 mL/hr/kg (≅20--35 mL/min/1.73 m^2^=1,200--2,100 mL/hr/1.73 m^2^) is considered sufficiently high \[[@b42-kjp-2018-06996],[@b43-kjp-2018-06996]\]; in this way, effluent volume is calculated. Then, the effluent rate is ideally equal to the sum of the DFR and replacement fluid flow rate (RFFR), the ratio of which is set by the physician. When HD:HF=1:1, DFR and RFFR can be set as 10--17.5 mL/hr/kg. In practice, the delivered CRRT may not be equal to the prescribed dose; therefore, prescription should be 120%--125% of the computed clearance \[[@b41-kjp-2018-06996]\].

When higher clearance is required, such as in hyperammonemia, DFR can be set to more than 2,100 mL/hr/1.73 m^2^.

5. Calculation of BFR
---------------------

A minimum BFR of 30--50 mL/min is necessary for CRRT; the BFR should be up to 400 mL/min/BSA 1.73 m^2^ (250 mL/min), or 10--12 mL/kg/min for neonates and infants (weight\<5 kg), 5--10 mL/kg/min in children (weight\<30 kg), and 2--5 mL/kg/min for older children (weight≥30 kg). BFR is supposed to be 5--10 fold higher than DFR or RFFR. Ultrafiltrate (removed fluid from the plasma) should be less than 20% of the plasma; therefore, plasma flow rate (BFR×\[1-hematocrit\]) should be more than 5 times the ultrafiltration rate. Ultrafiltration rate is the sum of RFFR (which is removed as convection) and patient removal rate (PRR, \[total input−total output+desired fluid removal\]/24). Therefore, BFR should be larger than (5×\[RFFR+PRR\]/60 min)/(1−hematocrit).

6. Anticoagulation
------------------

Anticoagulation is necessary to maintain extracorporeal circulation. Systemic anticoagulation with heparin (100 units/mL solution, 10--25 units/kg as loading and 5--10 units/kg/hr as maintenance) is most commonly performed; however, bleeding-related complications are common, and heparin-induced thrombocytopenia is also a concern. Nafamostat mesylate (Futhan \[SK chemicals, Seoul, Korea\], 0.1--1 mg/kg/hr) is a short-acting (half-life, 5--8 minutes) agent associated with fewer bleeding-related complications than heparin is. However, regardless of whether heparin or nafamostat mesylate is used, activated clotting time should be monitored regularly. Anticoagulation-free, intermittent saline flushing can be performed for patients with a higher risk of bleeding.

7. When to end CRRT
-------------------

When urine output recovers to \>400 mL/day in adults and renal creatinine clearance recovers to \>20--35 mL/min/1.73 m^2^, CRRT can be discontinued \[[@b44-kjp-2018-06996]\].

\(1\) Secure vascular access for dialysis

\(2\) Decide the filter/membrane of CRRT considering the BSA of the patient, and extracorporeal volume (\<8 mL/kg) vs. membrane surface area (≅BSA) and circuit volume (blood/albumin priming, if necessary)

\(3\) Choose the CRRT fluid considering phosphorous/potassium concentration

\(4\) Decide the mode of CRRT; CVVHDF (HD+HF), CVVHD (\[continuous venovenous hemodialysis\], HD only), CVVHF (\[continuous venovenous hemofiltration\], HF only)

\(5\) Decide the intensity of CRRT. Effluent flow rate=20--35 mL/hr/kg

\(6\) Calculate BFR (30--50 mL/min to ≤400 mL/min/1.73 m^2^)

\- 10--12 mL/kg/min (\<5 kg), 5--10 mL/kg/min (\<30 kg), 2--5 mL/kg/min if older (≥30 kg)

\- 5--10×DFR or RFFR

\- ≥(5×\[RFFR+PRR\]/60 min)/(1−hematocrit)

\(7\) Anticoagulation with regular monitoring of activated clotting time

\- Heparin loading 10−25 units/kg & 5−10 units/kg/hr as maintenance

\- Nafamostat mesylate 0.1−1 mg/kg/hr

\(8\) Monitor blood pressure, body weight, coagulation, chemistry (phosphorous, potassium, magnesium, pH q 6--8 hours), and effluent volume frequently

\(9\) Consider removal of nutrients and medication via CRRT

Prognosis of AKI: AKI to CKD transition
=======================================

AKI may cause permanent damage to the kidney by reducing the renal mass, causing renal medullary injury that is highly sensitive to ischemic injury during AKI, and following maladaptive repair and tubular atrophy \[[@b45-kjp-2018-06996],[@b46-kjp-2018-06996]\]. A meta-analysis showed that adult patients with AKI have more than 8.8 fold higher risk of CKD and more than 3 fold higher risk for ESRD \[[@b46-kjp-2018-06996],[@b47-kjp-2018-06996]\]. KDIGO guidelines recommend that patients with AKI should be followed up at 3 months after recovery from AKI, for renal function, blood pressure, and proteinuria \[[@b29-kjp-2018-06996]\]. As the increased risk of CKD years after AKI episodes is well known ([Fig. 3](#f3-kjp-2018-06996){ref-type="fig"}) \[[@b47-kjp-2018-06996]-[@b52-kjp-2018-06996]\], long-term follow-up of such patients is necessary. In addition, patients should be educated to avoid exposure to nephrotoxins such as NSAIDs and radiocontrast agents, and to actively undergo treatment for diabetes, hypertension, and proteinuria, if present.

Potential interventions of AKI
==============================

Through understanding the pathophysiology of AKI, potential therapeutic interventions, such as anti-inflammatory agents including recombinant alkaline phosphate \[[@b53-kjp-2018-06996]\], costimulatory molecule CD28 receptor antagonist \[[@b54-kjp-2018-06996]\], antioxidants, vasodilator-calcium sensitizer levosimendan \[[@b55-kjp-2018-06996]\], apoptosis inhibitors (p53 siRNA) and repair agents including bone morphogenetic protein-7 receptor agonist hepatocyte growth factor, and mesenchymal stem cells, are now under consideration \[[@b53-kjp-2018-06996]\].

Conclusion
==========

AKI is common in critically ill children and is associated with a very poor outcome. As there is no proven effective pharmacological intervention for AKI, prevention and early detection are important. To prevent and recover from AKI, optimization of volume status and circulation, avoidance of nephrotoxic agents, and sufficient nutritional support are necessary. CRRT continues to be increasingly performed for treating severe AKI. Novel biomarkers and potential therapeutic interventions for AKI are being investigated.
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###### 

Kidney Disease: Improving Global Outcomes definition and staging of acute kidney injury \[[@b2-kjp-2018-06996],[@b11-kjp-2018-06996]\]

  Stage   Serum creatinine                                                                                                                                                                                           Urine output
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  1       1.5 to 1.9 times baseline or ≥0.3 mg/dL (≥26.5 μmol/L) increase                                                                                                                                            \<0.5 mL/kg/hr for 6 to 12 hr
  2       2.0 to 2.9 times baseline                                                                                                                                                                                  \<0.5 mL/kg/hour for ≥12 hr
  3       3.0 times baseline or increase in serum creatinine to ≥4.0 mg/dL (≥353.6 μmol/L) or initiation of renal replacement therapy or in patients \<18 years a decrease in eGFR to \<35 mL/minute per 1.73 m^2^   \<0.3 mL/kg/hr for ≥24 hours or anuria for ≥12 hr

###### 

Common causes of acute kidney injury

  Category          Mechanism                    Examples
  ----------------- ---------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prerenal          Hypovolemia                  Poor oral intake, vomiting, diarrhea, hemorrhage, hypoalbuminemia
                    Cardiac failure              Heart failure
                    Renal vasoconstriction       Medications (NSAIDs, ACEi/ARB, calcineurin inhibitor)
                    Systemic vasodilation        Sepsis
  Intrinsic renal   Glomerular injury            Postinfectious glomerulonephritis, lupus nephritis, IgA nephropathy, Henoch-Schönlein purpura nephritis, pauciimmune glomerulonephritis, antiglomerular basement membrane nephritis
                    Tubulointerstitial injury    Medications (NSAIDs, antibiotics, chemotherapy agent, contrast), infection, lymphoproliferative disease, rhabdomyolysis, tumor lysis syndrome, ischemia
                    Vascular injury              Renal artery stenosis, thrombotic microangiopathies, thrombosis, emboli
  Postrenal         Renal pelvis obstruction     Stones
                    Ureteral obstruction         Ureteropelvic junction obstruction, ureterovesical junction obstruction, ureterocele, stones, cancer
                    Bladder outlet obstruction   Post urethral valve, neurogenic bladder, hemorrhagic cystitis, cancer, strictures

NSAID, nonsteroidal anti-inflammatory drug; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.

###### 

Exposures and susceptibilities for nonspecific acute kidney injury \[[@b2-kjp-2018-06996]\]

  Exposures                                                  Susceptibilities
  ---------------------------------------------------------- ---------------------------------------
  Sepsis                                                     Dehydration or volume depletion
  Critical illness                                           Advanced age
  Circulatory shock                                          Female gender
  Burns                                                      Black race
  Trauma                                                     Chronic kidney disease
  Cardiac surgery (especially with cardiopulmonary bypass)   Chronic diseases (heart, lung, liver)
  Major noncardiac surgery                                   Diabetes mellitus
  Nephrotoxic drugs cancer                                   Anemia
  Radiocontrast agents                                       
  Poisonous plants and animals                               

###### 

Recommended vascular access size, available in Korea in 2018

  Body weight       Access
  ----------------- ----------------------------------------------
  Newborn to 9 kg   6.5--7F dual lumen (Gambro)
  9--30 kg          8--9F dual lumen (Covidien/Gambro/MedComp)
  \>30 kg           10--12F dual lumen (Covidien/Gambro/MedComp)

Length: 10--12 cm

Location: right internal jugular vein (more straight route), femoral vein, or left internal jugular vein.

###### 

Choice of filter/membrane for continuous renal replacement therapy, available in Korea in 2018

  Content                            Baxter    Fresenius medical care                                              
  ---------------------------------- --------- ------------------------ --------- --------- ----------- ---------- ----------
  Surface area (m^2^)                0.2       0.6                      1.0       0.2       0.75        1.4        1.8
  Application (based on weight)      \<10 kg   \>10 kg                  \>30 kg   \<10 kg   20--40 kg   \>40 kg    \>40 kg
  Extracorporeal blood volume (mL)   60        93                       152       72        135         240        270
  Blood flow rate (mL/min)           20--100   50--180                  75--400   10--100   50--200     100--350   200--500
  Sieving coefficient                                                                                              
   Urea                              1         1                        1         \-        \-          \-         \-
   Vitamin B12                       1         1                        1         1         1           1          1
   Inulin                            0.92      0.96                     0.96      1         1           1          1
   Beta2-microglobulin               \-        \-                       \-        0.65      0.65        0.65       0.65
   Myoglobin                         \-        0.58                     0.58      \-        \-          \-         \-
   Albumin                           \<0.01    \<0.01                   \<0.01    0.001     0.001       0.001      0.001

CRRT, continuous renal replacement therapy; SCUF, slow continuous ultrafiltration; CVVHDF, continuous venovenous hemodiafiltration.

###### 

Choice of continuous renal replacement therapy fluid, available in Korea in 2018

  Component           Baxter   Fresenius medical care                               
  ------------------- -------- ------------------------ ------- ------- ----- ----- -----
  Na^+^ (mEq/L)       140      140                      140     140     140   140   140
  K^+^ (mEq/L)        0        2                        4       4       0     2     4
  Cl^−^ (mEq/L)       109.5    111.5                    113.5   115.9   109   109   113
  Ca2^+^ (mEq/L)      1.75     1.75                     1.75    1.25    1.5   1.5   1.5
  HCO~3~^−^           32       32                       32      30      35    35    35
  Lactate (mEq/L)     3        3                        3       0       0     0     0
  Phosphate (mEq/L)   0        0                        0       1.2     0     0     0
  Mg^2+^ (mEq/L)      0.5      0.5                      0.5     0.6     0.5   0.5   0.5
  Glucose (mEq/L)     0        6.1                      6.1     0       5.6   5.6   5.6
